L01EL Bruton's tyrosine kinase (BTK) inhibitors
ATC group of level 4 – chemical subgroup · in plain English: targeted cancer medicines (kinase inhibitors)
This site has the patient leaflet or the SPC of 8 medicines in this group and its subgroups.
- 7 prescription only (POM)
- 1 no longer supplied or not available
Place in the ATC classification
- L Antineoplastic and immunomodulating agents 1,791 medicines
- L01 Antineoplastic agents 1,025 medicines
- L01E Protein kinase inhibitors, antineoplastic and immunomodulating agents 353 medicines
-
L01EL Bruton's tyrosine kinase (BTK) inhibitors 8 medicines
- L01EL01 ibrutinib 5 medicines
- L01EL02 acalabrutinib 1 medicine
- L01EL03 zanubrutinib 2 medicines
-
L01EL Bruton's tyrosine kinase (BTK) inhibitors 8 medicines
- L01E Protein kinase inhibitors, antineoplastic and immunomodulating agents 353 medicines
- L01 Antineoplastic agents 1,025 medicines
Active substances in the group
- Acalabrutinib 1 medicine
- Ibrutinib 5 medicines
- Zanubrutinib 2 medicines
Medicines in the group and its subgroups
| Medicine | Legal category |
|---|---|
| Brukinsa 160 mg film-coated tablets (L01EL03 zanubrutinib) | Prescription only (POM) |
| Brukinsa 80 mg hard capsules SPC (L01EL03 zanubrutinib) | Prescription only (POM) |
| Calquence 100 mg film-coated tablets (L01EL02 acalabrutinib) | Prescription only (POM) |
| Imbruvica 140 mg film-coated tablets SPC (L01EL01 ibrutinib) | Prescription only (POM) |
| Imbruvica 140 mg hard capsules SPC no longer supplied (L01EL01 ibrutinib) | – |
| Imbruvica 280 mg film-coated tablets (L01EL01 ibrutinib) | Prescription only (POM) |
| Imbruvica 420 mg film-coated tablets SPC (L01EL01 ibrutinib) | Prescription only (POM) |
| Imbruvica 560 mg film-coated tablets SPC (L01EL01 ibrutinib) | Prescription only (POM) |
Other groups of the same level
- L01EA BCR-ABL tyrosine kinase inhibitors 101 medicines
- L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors 40 medicines
- L01EC B-Raf serine-threonine kinase (BRAF) inhibitors 6 medicines
- L01ED Anaplastic lymphoma kinase (ALK) inhibitors 14 medicines
- L01EE Mitogen-activated protein kinase (MEK) inhibitors 10 medicines
- L01EF Cyclin-dependent kinase (CDK) inhibitors 13 medicines
- L01EG Mammalian target of rapamycin (mTOR) kinase inhibitors 27 medicines
- L01EH Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors 4 medicines
- L01EJ Janus-associated kinase (JAK) inhibitors 18 medicines
- L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors 12 medicines
- L01EM Phosphatidylinositol-3-kinase (Pi3K) inhibitors 6 medicines
- L01EX Other protein kinase inhibitors 94 medicines
Other names of the ATC group
Sources
- Patient leaflets and SPCs: the MHRA product information (products.mhra.gov.uk) and the European Medicines Agency (EMA)
- Active substances, ATC codes and legal categories: the NHS Dictionary of Medicines and Devices (dm+d), NHS Business Services Authority
- World Health Organization (WHO): ATC/DDD classification, group L01EL
Contains public sector information licensed under the Open Government Licence v3.0.
Ask your doctor or pharmacist which medicine is right for you.